Still Mistreating the Elderly with Psychiatric Drugs: Antipsychotics
The percentage of seniors in the United States prescribed potentially deadly antipsychotic drugs increases with age. A new study reveals that in the face of serious risks of strokes, fractures, kidney injuries, and death, over seventy-five percent of seniors given antipsychotics do not have a diagnosis for a mental disorder.
Still Mistreating the Elderly with Psychiatric Drugs: Benzodiazepines
Despite safety concerns, a new study reveals that there has been no change in the use of benzodiazepines in the elderly from 2001 to 2010.
First Federal Zoloft Birth Defect Trial Scheduled
In a bellwether case, plaintiffs allege that Pfizer did not adequately warn patients that Zoloft (sertraline) would cause birth defects. The case is scheduled in Federal Court in March, and the verdict will have significant implications for future suits.
“Kids in Foster Care Three Times More Likely to be Diagnosed with ADHD”
PsychCentral presents a new study from the Center for Disease Control and Prevention (CDC) that found that foster care children are three times more likely than other children on Medicaid to receive a diagnosis of ADHD. Overall, more than one in four children in foster care receive such a diagnosis. CDC statistician Melissa Danielson interpreted these results as revealing a “substantial need” for more medical and behavioral services for kids in foster care.
More Than Two-Thirds of Antidepressants Prescribed Against Guidelines
Results of a new study reveal that sixty-nine percent, or more than two-thirds, of patients prescribed antidepressant drugs have never, in their medical history, met the criteria for major depression. The study, published in the Journal of Clinical Psychiatry this month, also found that several demographic factors, like race and gender, were associated with the prescription of antidepressants.
Confusion Over Antipsychotic Dosing Data in RAISE Study
Yesterday, the New York Times reported that schizophrenia patients in an experimental treatment program (RAISE) who experienced better outcomes had been on lower doses of antipsychotics than normal. However, the article published in the American Journal of Psychiatry on Tuesday did not divulge any data on the varying antipsychotic drug doses in the different study groups.
“Controversial ‘Female Viagra’ Hits the Market, New Questions Arise”
Despite concerns about the drug’s necessity, effectiveness, and side-effects, Flibanserin (Addyi) has come to market as the first drug designed to increase sexual desire in women
Over Ten Thousand Unfiled Claims Against Risperdal Over Breast Growth in Young Boys
Johnson & Johnson is exposed to personal injury and product liability lawsuits over the failure to warn about Risperdal gynecomastia side effects in boys.
“Holding Big Pharma Accountable: Why Suing the Pharmaceutical Industry Isn’t Working”
Writing for the Huffington Post, Caroline Beaton looks into how drugs continue to make billions in sales even after they lose lawsuits for fraud and misconduct. “The persistence of Big Pharma's fraud despite ubiquitous legal action suggests that our present efforts to hold the industry accountable are ineffective,” Beaton writes. “New polices in motion will make potentially unsafe drugs even easier to bring to market and promote.”
Report Calls For Policy Changes In Response To Dependence and Withdrawal From Prescribed Drugs
Statistics from the UK reveal that prescriptions for painkillers and antidepressants continue to rise despite concerns over dependence and debilitating withdrawal effects. The British Medical Association (BMA) Board of Science has released a report that acknowledges changes to medical practice, research and policy necessary for addressing the dependence and withdrawal effects of benzodiazepines, opioids, and antidepressants.
“US Opioid Epidemic Fueled by Prescribing Practices”
Medscape Psychiatry reports that the “man-made epidemic” of opioid abuse in the United States is the result of over-prescription and poor research.
Genetic Tests Marketed to Psychiatrists Not Supported by Research
With the explosion of genetic testing and the emerging field of pharmacogenetics, patients can now take a DNA test and receive psychiatric drug recommendations customized to fit their genetic makeup. In an editorial for the latest issue of the Journal of Nervous and Mental Disease, Columbia University Psychiatrist Robert Klitzman warns that clinicians need to be aware of the limitations of these genetic tests being marketed to them.
“Treating Parkinson’s Psychosis With Antipsychotics May Boost Death Risk”
The Psychiatric Advisor reports on new research from King’s College London that suggests that antipsychotics can cause serious harm to people with Parkinson’s.
“Club Drug Ketamine Gains Traction As A Treatment For Depression”
NPR reports on how ketamine is being used off-label to treat depression.
“Report Finds Florida Foster Kids Put on Psychotropic Drugs Without Following Proper Procedures”
After the 2009 suicide of a seven-year-old foster kid who had been on two “black box” medications intended for adults, Florida updated its policies to protect vulnerable children from over-prescription. Unfortunately, according to a report by Orlando Weekly, “foster children are still being put on psychotropic medications without caregivers following proper procedures.”
Prescription Stimulant Use is Associated with Earlier Onset of Psychosis
Individuals diagnosed with psychotic disorders have an earlier onset of psychosis if they have previously been exposed to prescription stimulants, according to new research currently in press in the Journal of Psychiatric Research.
Murphy’s Mental Health Bill a Threat to Civil Liberties
In an Op-ed for the Times Union, Madeleine Ringwald explains how the Helping Families in Mental Health Crisis Act “would severely disable protection and advocacy organizations from protecting the civil, legal and human rights of people in mental health services.” “Whether you examine it through a scientific, civil rights or bottom-line lens, Murphy's bill should appall you,” she writes. “Any legislation that bolsters institutionalization at the cost of community-based services seeks not to help those with mental health needs, but help society find ways to hide, suppress and silence them.”
Study Links SSRIs to Violent Crime in Youth
Individuals between the ages of 15 and 24 are more likely to commit a violent crime if they are taking an SSRI antidepressant than if they are not, according to new research out of Sweden. The study published in PLoS Medicine on Tuesday, suggests "warnings about the increased risk of violent behavior among young people taking SSRIs might be needed.”
HuffPo Features 15 Part DocuSerial on Risperdal Corruption
Huffington Post and journalist Steve Brill have combined to launch a 15 part series about how Johnson & Johnson illegally violated FDA restrictions by pushing the antipsychotic drug, Risperdal, for use with adolescents and the elderly. The series, entitled “America’s Most Admired Lawbreaker,” launched yesterday and will include mixed media, videos, podcasts, source documents, as well as 15 written chapters. Click more for a synopsis of part 1.
Drug Treatment for Borderline Personality Disorder Not Supported By Evidence
New research published in the August issue of Psychiatric Annals evaluates the results of randomized control trials on the use of various psychotropic drugs for patients diagnosed with borderline personality disorder (BPD). Despite the “American Psychiatric Association’s practice guidelines endorsement of SSRIs as first-line therapies for BPD,” the results of the meta-analysis reveal that pharmacotherapy in BPD is “not supported by the current literature,” and “should be avoided whenever possible.”
Pennsylvania Foster Kids Prescribed Too Many Psychotropic Drugs
Amid growing criticism about the over-prescription of psychotropic medication in foster care, Pennsylvania commissioned PolicyLab to conduct an analysis of the use of psychiatric drugs among all of the state’s Medicaid-enrolled children. The report, released in June, found that the rate of psychotropic prescriptions among youth in Medicaid and foster care was higher than previously reported.
“Antipsychotics May Be Pushed On Those with Intellectual Disabilities”
Psych Central covers findings published in BMJ revealing that many people in the U.K. with intellectual disabilities are being prescribed antipsychotic drugs. The study’s lead author comments: “People who show problem behaviors, along with older people with intellectual disability or those with co-existing autism or dementia, are significantly more likely to be given an antipsychotic drug, despite this being against clinical guidelines and risking possible harm.”
“Antipsychotic Use in Youth Without Psychosis: A Double-edged Sword”
This month’s issue of JAMA Psychiatry ran an editorial commenting on recent research revealing that the majority of youth prescribed antipsychotics have not been diagnosed with a mental disorder.
Members of FDA Advisory Committee Offer Perspectives on Flibanserin Approval in JAMA
In the September issue of The Journal of the American Medical Association (JAMA) three FDA advisory committee members describe the convergence of factors that made the committee’s recommendation to approve flibanserin especially challenging and politically charged.
“Fears That Antipsychotic Drugs Being Used as ‘Chemical Cosh’ in Disability Care”
An editorial in the Guardian discusses the fact that the number of people with intellectual or learning disabilities “who are being treated with psychotropic drugs far exceeds those with mental illness.” The authors of a new study examining the overuse of psychotropic drugs on people with learning disabilities, published this month in BMJ, argue: “If people without mental illness are given psychotropic drugs… it is probably to control their behavior.”